F&O Radar | Deploy Broken Wing strategy in ICICI Bank to gain from bullish outlook (29-10-2024)
ICICI Bank shares are currently trading at Rs 1,292.85, continuing their long-term uptrend. The stock recently broke out of a consolidation phase after a pullback from higher levels and has stabilized near a key demand zone, indicating a potential trend reversal.
North India leads NSE’s investor base at 3.7 cr followed by West at 3.2 cr and South at 2.1 cr (29-10-2024)
The retail investors are on continues surge in the Indian stock markets, a recent report by National Stock Exchange (NSE), highlighted that around 37 lakh new retail investors joined NSE in September taking the total investor base to 10.37 crores.
30% price surge in gold since last Dhanteras. Here’s your 6-point shopping guide (29-10-2024)
Gold sees a 30% price surge since last Dhanteras. Experts suggest continued investment, forecasting potential returns of 10-12% by the next Dhanteras amid geopolitical and economic uncertainties. Options include physical gold, ETFs, digital gold, and futures, though SGBs face liquidity challenges.
Buy ICICI Bank, target price Rs 1,370: HDFC Securities (29-10-2024)
HDFC Securities recommends buying ICICI Bank shares with a target price of Rs 1,370. ICICI Bank showed strong financial performance in the latest quarter and reported a net profit of Rs 12,947.77 crore. The bank growth was driven by business banking, SME, rural and credit card segments, with healthy deposit growth and maintained asset quality.
Sun Pharma shares in spotlight after Q2 profit rises 28% YoY to Rs 3,040 crore. Should you invest? (29-10-2024)
Sun Pharma Share Price: Sun Pharma shares are poised for attention on Tuesday after the company reported a 28% YoY growth in consolidated net profit, reaching Rs 3,040 crore in the second quarter. Revenue from operations rose by 9% YoY to Rs 13,291 crore.
Afcons Infrastructure IPO closes today (29-10-2024)
The IPO so far received only a lukewarm response from investors
Hot Stocks: Brokerage view on Bharti Airtel, Macrotech Developers, BPCL, Federal Bank and Sun Pharma (29-10-2024)
Nomura maintains a buy rating on Macrotech Developers with a target price of Rs 1,600, citing strong Q2 performance and anticipated 20% YoY pre-sales growth. For BPCL, Nomura raises the target to Rs 380 despite lower results. Nuvama and Jefferies also maintain buy ratings on Federal Bank (target Rs 235) and Sun Pharma (target Rs 2,150), respectively, highlighting strong performance and growth potential.
No, poll workers aren’t handing out Sharpies to invalidate ballots. (29-10-2024)
The writing utensils figured prominently in conspiracy theories in previous elections. But they’re often fine to use on paper ballots.
E2E Networks Ltd – Listed small Cloud computing player (29-10-2024)
this gives some comfort… but i didnt understand one thing – e2e has better numbers on all 6 metrics than google, yet google overall rating is higher. why?